MedTrace Logo

Comparison of Two Different Doses of Phenylephrine on Oxytocin Hemodynamic Effect

NCT07420127 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2026-02-24

No results posted yet for this study

Summary

Cesarean section is one of the commonly performed surgical procedures in the world. Once baby is delivered during the surgical procedure anesthesiologist administer Oxytocin drug through IV cannula which helps the Uterus to contract so that excessive blood loss doesnt occur. But this is associated with fall in blood pressure frequently requiring administration of medications to treat low blood pressure. The most frequently used drug is phenylephrine which can administered along with oxytocin to prevent fall in blood pressure. This study will compare to different doses of Phenylephrine to prevent fall in blood pressure.

Conditions

  • Phenylephrine
  • Cesarean Birth

Interventions

DRUG

Phenylephrine bolus 75 micrograms

After delivery of Baby during C section, patient will be administered 3 IU of Oxytocin over 3 minutes along with 75 micrograms of Phenylephrine Intravenously.

DRUG

Phenylephrine bolus 50 micrograms

After delivery of Baby during C section, patient will be administered 3 IU of Oxytocin over 3 minutes along with 50 micrograms of Phenylephrine Intravenously.

Sponsors & Collaborators

  • Rawalpindi Medical College

    lead OTHER

Principal Investigators

  • Jawad Zahir · Head of Department of Anesthesia

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-13
Primary Completion
2026-07-13
Completion
2026-07-13

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07420127 on ClinicalTrials.gov